Document is current
Any future updates will be listed below
-
Authors
Liu, Xiaoguang https://orcid.org/0000-0001-6977-5128
Nie, Litong https://orcid.org/0000-0002-0326-4517
Zhang, Yilei https://orcid.org/0000-0003-1407-0301
Yan, Yuelong https://orcid.org/0000-0001-8495-6445
Wang, Chao
Colic, Medina https://orcid.org/0000-0003-1442-1589
Olszewski, Kellen
Horbath, Amber
Chen, Xiong
Lei, Guang https://orcid.org/0000-0002-3282-0666
Mao, Chao
Wu, Shiqi
Zhuang, Li
Poyurovsky, Masha V.
James You, M.
Hart, Traver
Billadeau, Daniel D.
Chen, Junjie https://orcid.org/0000-0002-1493-2189
Gan, Boyi https://orcid.org/0000-0001-8884-6040
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R35GM130119, R01DK107733, R01CA244144, R01CA247992)
- License Information
-
More Information
Article History
Received: 16 March 2022
Accepted: 12 January 2023
First Online: 6 February 2023
Competing interests
: B.G. reports receiving consultation fees from Guidepoint Global, Cambridge Solutions and NGM Bio, and is an inventor with patent applications involving targeting ferroptosis in cancer therapy. K.O. is a full-time employee of the Barer Institute and a former full-time employee of Kadmon Corporation. M.V.P. is a full-time employee of Kadmon Corporation, a Sanofi Company. The remaining authors declare no competing interests.
